In Roman religion, Portunus was the god of harbors, ports, and thresholds. He held the literal keys to the port gate and governed the moment of departure: the precise transition from the safety of the dock to the irreversibility of open water. The Romans didn't consider a harbor a place to wait indefinitely. They considered it a place to prepare deliberately. A vessel that left port underprepared didn't just fail its own voyage. It consumed the investment of every person who built it, loaded it, and expected its return. Portunus held the gate not to keep ships in, but to ensure that when they left, they were ready for what came next.
As a product manager (PM) in RUO life science tools, every product you bring to market has a Portunus moment. The soft launch is your harbor. Not a lesser version of your full commercial release. The controlled passage point, where you collect signal before you commit to a launch posture you can't easily reverse.
Most soft launches in life sciences fail before they start because the PM and NPD team has never agreed on what the soft launch is actually for.
Ask three stakeholders why you're doing a soft launch and you'll get three different answers. Commercial leadership thinks it means "limited distribution while we finish sales training." R&D thinks it means "more time to close the last two validation gaps." Marketing thinks it means "early access pricing to seed a few reference sites." None of them is wrong, exactly. But none of them is running the same launch.
That ambiguity is expensive. When the soft launch is everything to everyone, it becomes a container for unresolved cross-functional tension rather than a disciplined market learning exercise. Launch timelines drift. Exit criteria get renegotiated. And the PM ends up holding accountability for a delay that was never actually about product readiness.
The second failure mode is the opposite: the soft launch that never happens at all. Commercial pressure, investor timelines, or a competitive sighting triggers a push to skip directly to full release. The qPCR assay kit ships to 200 accounts before your field application scientists (FASes) have seen a single real customer workflow. The imaging system hits distribution before anyone has confirmed the Z-stack calibration issue observed in late-stage development is resolved under real lab conditions. This isn't boldness. It's noise generation at scale.
The soft launch done well solves both problems. It forces clarity on what signal you need before full commercial commitment, and it creates the conditions to collect that signal cleanly.
First, a distinction worth making explicit. A beta-site is a pre-commercial arrangement: the product is still being refined, sites get early or free access in exchange for tolerating imperfection and providing development feedback. A soft launch is different. By the time you soft launch, the product has cleared its development gates. Your soft launch cohort are paying customers, ideally at or near list price, not participants in a development program. If you're asking a soft launch cohort to tolerate imperfection, you've launched too early or you're running a beta-site under a different name.
This is where Everett Rogers' Diffusion of Innovations framework earns its place. Rogers draws a hard line between your innovator and early adopter segment and your early majority, and the distinction matters for soft launch design. Early adopters don't move because a product is perfect. They move because they evaluate on scientific merit, make purchasing decisions without requiring peer precedent, and have the organizational credibility to influence the early majority who won't move without it. That downstream influence is exactly why you recruit them for your soft launch cohort. Not because they'll tolerate an unfinished product, but because their validated endorsement unlocks the next wave of commercial adoption. If your soft launch accidentally pulls in early majority buyers, procurement-driven, risk-averse, measuring you against an incumbent, your signal will be skewed toward objections you aren't yet positioned to answer and you'll extend the launch chasing the wrong feedback.
Used correctly, a soft launch gives you three things that no amount of internal preparation can substitute for. It tells you whether your positioning matches the language customers actually use to describe the problem. It tells you whether your commercial infrastructure, FAS training, tech support protocols, distributor onboarding, can scale without the PM as a backstop. And it tells you who your real advocates are before you need them at full commercial velocity.
The difference between a soft launch that generates usable signal and one that generates organizational theater usually comes down to these decisions:
| Do This | Not This | |||
| 1 |
|
Recruit early adopters, not early customers. Identify 4-6 labs or core facilities that will evaluate deliberately, give structured feedback, and have the credibility to influence downstream purchasing decisions. |
|
Acquire whoever your distributor rep can get in the door. Early customers give you revenue. Early adopters give you signal. These are not the same thing. A lab that bought your ELISA kit because it was on a preferred vendor list will not tell you “why the protocol feels clunky at step 6.” |
| 2 |
|
Define your exit criteria before you start. Set 3 measurable gate criteria in advance, and keep them focused on commercial readiness, not product performance. For a flow cytometry panel soft launch, that might mean: FAS team can independently troubleshoot panel optimization without PM support; at least 2 sites have reordered at list price with no discount negotiation; and your positioning language matches the words customers use unprompted when describing the problem to a colleague. |
|
Decide when you're "ready" by feel. Without defined exit criteria, your soft launch will absorb every open question from every functional stakeholder. R&D wants one more data point. Regulatory wants one more qualification run. "Ready" becomes a moving target and the PM carries the delay. |
| 3 |
|
Track commercial motion, not product performance. Your soft launch metrics should answer commercial questions. Do customers reorder at list price without a relationship discount? Do they describe the problem in your positioning language without prompting? Can your FAS team run a demo and close a follow-on order without you in the room? These signals tell you whether your commercial motion is ready to scale. |
|
Measure product performance as if development isn't finished. If you're still measuring yield consistency, CV thresholds, or protocol reproducibility at soft launch, the product wasn't ready to leave development. Collecting product performance data at this stage means you're running a beta-site, not a soft launch. The commercial team cannot build on that signal. |
| 4 |
|
Set a hard exit date and communicate it. A 90-day soft launch with defined gate criteria is a strategic instrument. Communicate the date to your cross-functional team before you start. When new questions emerge during the soft launch, they go on the V1.1 roadmap, not the V1.0 exit checklist. |
|
Let the soft launch run until "everyone is comfortable." Comfort is not a gate criterion. A 9-month soft launch with shifting goalposts is not risk management. It is organizational indecision with better vocabulary, and it costs more than a faster, imperfect full launch in most RUO markets. |
| 5 |
|
Test your pricing discipline explicitly. A soft launch is your last low-stakes opportunity to confirm customers will pay list price without a relationship discount. Track whether early adopters reorder at full price and whether new sites in the cohort purchase without negotiation. If they won't pay list price now, your pricing model has a problem that full commercial release will make far more expensive to diagnose. |
|
Use early adopter pricing as a default soft launch benefit. Discounting to get sites into the soft launch cohort corrupts the commercial signal entirely. You will never know whether the product sells or the discount did. That ambiguity follows you into full commercial release and gives your sales team a pricing precedent they will struggle to walk back.
|
Treating a soft launch as default process regardless of context is just as risky as skipping it. Here are three situations where the soft launch adds cost without adding proportional signal.
Proven consumable line extensions with identical workflows. If you're adding a new lot size or concentration variant to an ELISA kit line with an established customer base and no new application claims, you already have the signal. Your existing customers are the soft launch cohort. Running a formal limited-access phase adds 60-90 days of delay for data you already have.
Markets too small for staged access to matter. In highly specialized RUO segments, your total addressable market might be 30 core facilities globally. A soft launch with 6 sites isn't limiting access. It is your launch. Call it what it is, instrument it properly, and avoid the organizational overhead of treating it as a distinct phase.
Competitive windows with asymmetric timing risk. Sometimes the cost of a 90-day soft launch exceeds the cost of an imperfect full launch. If a well-funded competitor has publicly announced a product in your exact application space and your product is functionally ready, the signal you'd collect in a soft launch may be less valuable than the market position you'd establish by moving first. This is a judgment call that requires honest competitive intelligence, not a reflex.
The test is simple: ask what specific question the soft launch will answer that you cannot answer any other way, and what decision that answer will enable. If you can't complete that sentence with something concrete, you may not need a soft launch. You may just need a better-instrumented full launch.
Here is the version of this conversation most PM content skips. In many life sciences organizations, the soft launch is not primarily a market learning exercise. It is a risk distribution mechanism.
When every functional stakeholder needs to sign off before the gate to full commercial release, the soft launch becomes a veto instrument. Nobody wants to be the person who greenlit a product that failed publicly. The soft launch extends the period during which accountability is shared and therefore diffuse. R&D can point to ongoing field data. Regulatory can point to open qualification items. Commercial can point to insufficient reference site density. The PM holds the timeline and absorbs the delay.
Quantify what this costs. Assume your liquid handler integration kit is priced at $8,500 and your full commercial velocity is 15 units per month. A 6-month soft launch extension costs you $765,000 in foregone revenue. It also costs 6 months of competitive exposure, 6 months of distributor momentum that stalls without a full commercial signal from you, and the reputational message to your most enthusiastic early adopters that you are not yet confident in your own product.
Protect yourself by defining exit criteria in writing before the soft launch begins, owned by a named decision-maker. Anything that surfaces during the soft launch that wasn't in the original gate definition goes on the roadmap. The moment you allow post-hoc feedback to expand your pre-launch definition of done, Portunus loses his keys and no ship leaves port.
Portunus didn't make voyages. He made voyages possible. His value was in the clarity of the threshold: you are here, preparing, or you are there, committed. There was no organizational purgatory in between.
A soft launch built on recruited early adopters, defined exit criteria, and a hard transition date gives you the same clarity.
You are generating signal, or you are in market. The harbor is not the destination.
Recruit your adopters. Define your gate. Set your date. Open it.